Analysts expect Edge Therapeutics Inc (NASDAQ:EDGE) to announce ($0.47) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Edge Therapeutics’ earnings. Edge Therapeutics posted earnings of ($0.33) per share in the same quarter last year, which suggests a negative year over year growth rate of 42.4%. The company is scheduled to report its next earnings report on Thursday, March 1st.
On average, analysts expect that Edge Therapeutics will report full year earnings of ($1.70) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($2.11) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Edge Therapeutics.
Several analysts recently weighed in on EDGE shares. Zacks Investment Research upgraded shares of Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Monday, November 6th. BidaskClub upgraded shares of Edge Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $17.00 price objective on shares of Edge Therapeutics in a research report on Thursday, January 18th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $20.00.
Shares of Edge Therapeutics (EDGE) opened at $12.85 on Friday. The firm has a market cap of $408.27, a PE ratio of -8.24 and a beta of 3.32. Edge Therapeutics has a 52-week low of $7.30 and a 52-week high of $13.76. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34.
In other news, insider Albert N. Marchio II sold 3,361 shares of Edge Therapeutics stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $10.00, for a total value of $33,610.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Brian A. Leuthner sold 2,500 shares of Edge Therapeutics stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $13.14, for a total transaction of $32,850.00. Following the completion of the transaction, the chief executive officer now directly owns 82,736 shares in the company, valued at $1,087,151.04. The disclosure for this sale can be found here. Insiders sold a total of 20,861 shares of company stock worth $215,760 in the last ninety days. Corporate insiders own 36.19% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. increased its position in shares of Edge Therapeutics by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 75,279 shares of the biotechnology company’s stock worth $773,000 after acquiring an additional 532 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Edge Therapeutics by 7.7% in the second quarter. California State Teachers Retirement System now owns 35,167 shares of the biotechnology company’s stock worth $361,000 after acquiring an additional 2,500 shares in the last quarter. Rhumbline Advisers increased its position in shares of Edge Therapeutics by 19.1% in the second quarter. Rhumbline Advisers now owns 19,960 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 3,195 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Edge Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 3,764 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Edge Therapeutics by 44.4% in the third quarter. Wells Fargo & Company MN now owns 17,249 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 5,307 shares in the last quarter. 50.22% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.47 Earnings Per Share” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/04/brokerages-anticipate-edge-therapeutics-inc-edge-to-announce-0-47-earnings-per-share.html.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Get a free copy of the Zacks research report on Edge Therapeutics (EDGE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.